



## ASX ANNOUNCEMENT

22 AUGUST 2019

### FY19 RESULTS CONFERENCE CALL

---

**22 August 2019** – Cann Group Limited (ASX: CAN) is pleased to advise it will host a conference call for investors and interested parties in conjunction with the release of its FY19 results on Tuesday 27 August 2019.

The call will feature Cann Group Chairman Allan McCallum and CEO Peter Crock.

There will be opportunity for questions from participants on the call.

#### **Call details**

**Australia:** Tuesday 27 August

(AEST – 11:30am)

(ACST – 11am)

(AWST – 9:30am)

**USA/Canada:** Monday 26 August

(Pacific daylight time – 6:30pm)

(Central daylight time – 8:30pm)

(Eastern daylight time – 9:30pm)

**UK:** Tuesday 27 August

(British summer time – 2:30am)

#### **Dial in numbers:**

Australia: 1800 908 299 or 1800 455 963

Hong Kong: 800 968 273

Singapore: 800 101 2702

Canada: 1855 624 0077

New Zealand: 0800 452 795

United Kingdom: 0800 051 1453

United States: 1855 624 0077

Participants can also register for the conference call by navigating to: <https://s1.c-conf.com/diamondpass/canngroup-10001863-invite.html>



**For further information please contact:**

Peter Crock  
CEO  
Cann Group Limited  
+61 3 9095 7088  
[contact@canngrouponlimited.com](mailto:contact@canngrouponlimited.com)

Clive Fanning  
Head of Investor Relations  
Cann Group Limited  
+61 498 000 762  
[clive.fanning@canngrouponlimited.com](mailto:clive.fanning@canngrouponlimited.com)

Matthew Wright  
NWR Communications  
+61 451 896 420  
[matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

**About Cann Group**

Cann Group is building a world-class business focused on breeding, cultivating and manufacturing medicinal cannabis for sale and use within Australia. The company has established research and cultivation facilities in Melbourne and is striving to provide access to medicinal cannabis for Australian patients. Cann Group has executed collaboration agreements that will enable it to establish a leading position in plant genetics, breeding, extraction, analysis and production techniques required to facilitate the supply of medicinal cannabis for a range of diseases and medical conditions. It was issued with Australia's first medicinal cannabis research licence in February 2017, in addition to Australia's first medicinal cannabis cultivation licence in March 2017. Aurora Cannabis Inc – one of Canada's largest listed medicinal cannabis company – is a cornerstone investor in Cann, with a 22.54% shareholding.